Carlton Hofferkamp & Jenks Wealth Management LLC Lowers Position in Johnson & Johnson (JNJ)
Carlton Hofferkamp & Jenks Wealth Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,809 shares of the company’s stock after selling 969 shares during the period. Johnson & Johnson comprises about 1.8% of Carlton Hofferkamp & Jenks Wealth Management LLC’s portfolio, making the stock its 14th largest position. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,281,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Americafirst Capital Management LLC bought a new position in Johnson & Johnson during the second quarter worth $101,000. Capital Asset Advisory Services LLC bought a new position in Johnson & Johnson during the second quarter worth $202,000. Terra Nova Asset Management LLC bought a new position in Johnson & Johnson during the first quarter worth $243,000. Independent Portfolio Consultants Inc. raised its position in Johnson & Johnson by 340.1% in the first quarter. Independent Portfolio Consultants Inc. now owns 3,076 shares of the company’s stock worth $333,000 after buying an additional 2,377 shares during the last quarter. Finally, Daiwa SB Investments Ltd. raised its position in Johnson & Johnson by 8.4% in the second quarter. Daiwa SB Investments Ltd. now owns 2,970 shares of the company’s stock worth $354,000 after buying an additional 230 shares during the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.41% during trading on Friday, hitting $119.24. The company had a trading volume of 4,799,292 shares. The stock’s 50-day moving average price is $118.85 and its 200 day moving average price is $117.07. The company has a market capitalization of $326.23 billion, a P/E ratio of 22.22 and a beta of 0.62. Johnson & Johnson has a 52 week low of $94.12 and a 52 week high of $126.07.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The firm earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. On average, equities research analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current year.
A number of research firms have weighed in on JNJ. Credit Suisse Group AG reaffirmed a “neutral” rating and set a $123.00 target price on shares of Johnson & Johnson in a report on Monday, September 19th. Wells Fargo & Co. reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. BMO Capital Markets reissued an “outperform” rating and set a $132.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 20th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a report on Friday, August 5th. Finally, Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.13 price objective for the company in a report on Tuesday, September 27th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $120.19.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares in the company, valued at approximately $19,728,953.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.